Clinical Pathological Study of Cognitive Impairment in Essential Tremor
Clinical Pathological Study of Cognitive Impairment in Essential Tremor
批准号:
8758709
负责人:
ELAN D LOUIS
金额:
$66.49万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-06-01 至 2015-05-31
关键词:
AccountingAgeAlzheimer&aposs DiseaseAmnestic DisorderAmyloid beta-ProteinAstrocytesAutopsyBrainCessation of lifeCharacteristicsClinicalClinical ResearchClinical dementia rating scaleCognitionCognitiveCognitive deficitsComplexCounselingCytoplasmic InclusionDataDementiaDevelopmentDiagnosisDiseaseEducationEpidemiologic StudiesEssential TremorExecutive DysfunctionFunctional disorderGenderGoalsGuidelinesImageImpaired cognitionImpairmentLeadLewy BodiesLinkMapsMatched GroupMemoryNatureNeocortexNerve DegenerationNeurobehavioral ManifestationsNeurofibrillary TanglesNeurologicPathologyPatientsPerformancePlant RootsProcessProgressive Supranuclear PalsyRelative RisksReportingResearchRiskRisk FactorsSensitivity and SpecificitySeveritiesShapesSideStructureSubgroupTauopathiesTemporal LobeTestingTimeTremorVascular Diseasesbasecase controlexecutive functionmild cognitive impairmentmotor disorderneuropsychologicalnovelprognosticpublic health relevancetau Proteinstau aggregationtau-1
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Although the most recognizable clinical feature of essential tremor (ET) is tremor, there is emerging evidence that non-motor features (esp. cognitive dysfunction) are present. A growing number of studies show that ET patients have poorer cognitive performance than age-matched controls. In some ET patients, the cognitive problems are severe. Also, recent epidemiological studies have demonstrated that ET patients are more likely to have mild cognitive impairment (MCI) than age-matched controls, and an increased risk of dementia. While ET appears to be a risk factor for the development of cognitive impairment, the cause is not currently known. The cerebellar basis for ET could contribute to cognitive impairment, yet there is other evidence that ET is associated with an increased risk of developing tau-related disorders (Alzheimer's disease [AD] and progressive supranuclear palsy [PSP]). This absence of a mechanistic understanding results in a difficult clinical predicament - there is presently no way to deduce whether a given ET patient, based on his/her observed cognitive features, has early AD, early PSP, or merely the expected cognitive profile of ET. We have no predictive guidelines for patients. What are the next steps? It is important to conclusively characterize the cognitive impairment of ET and to disentangle its component causes. The overall goal of the proposed research is to refine our understanding of this clinical-pathological entity. We aim to perform longitudinal neuropsychological examinations on 350 ET cases and postmortem neuropathological examinations on 110 of these who die over 5 years, matching them to 220 autopsied non-ET cases. The novel concepts/new hypotheses we now put forward are as follows: i) for reasons that are as yet unclear, ET itself predisposes to tauopathic changes in the brain; thus, by extension, even if one were to match for level of cognitive impairment (normal cognition, MCI, or mild dementia), ET cases would still have more tau pathology than non-ET cases, ii) the nature/features of the tauopathy of ET is likely to differ
from that of non-ET cases, iii) ET pathology alone, is likely to be the prime cause of cognitive deficits in a subgroup of ET cases, and iv) within the mix of ET cases, it should be possible to map certain cognitive profiles onto certain pathologies. Our 5-year proposal has two aims: AIM 1: To study the neuropathological basis of cognitive deficits in ET. AIM 2: To provide the first comprehensive characterization of cognition in ET and to demonstrate that the severity of certain cognitive deficits predicts non-ET pathology in ET. We expect that this research will elucidate the processes of dementia in ET and shape the counseling and treatment of ET patients with cognitive symptoms.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Environmental Epidemiology of Essential Tremor
-
批准号:9009000
-
项目类别:
-
资助金额:$84.79万
-
财政年份:2016
-
负责人:ELAN D LOUIS
-
依托单位:
Environmental Epidemiology of Essential Tremor
-
批准号:9229079
-
项目类别:
-
资助金额:$81.53万
-
财政年份:2016
-
负责人:ELAN D LOUIS
-
依托单位:
Environmental Epidemiology of Essential Tremor
-
批准号:9889181
-
项目类别:
-
资助金额:$3.46万
-
财政年份:2016
-
负责人:ELAN D LOUIS
-
依托单位:
Environmental Epidemiology of Essential Tremor
-
批准号:10214061
-
项目类别:
-
资助金额:$73.61万
-
财政年份:2016
-
负责人:ELAN D LOUIS
-
依托单位:
in Vivo Quantification of Cerebellar GABA and NAA in Essential Tremor
-
批准号:8613863
-
项目类别:
-
资助金额:$66.84万
-
财政年份:2013
-
负责人:ELAN D LOUIS
-
依托单位:
in Vivo Quantification of Cerebellar GABA and NAA in Essential Tremor
-
批准号:8734499
-
项目类别:
-
资助金额:$62.21万
-
财政年份:2013
-
负责人:ELAN D LOUIS
-
依托单位:
RISK FACTORS UNDERLYING ESSENTIAL TREMOR
-
批准号:7205920
-
项目类别:
-
资助金额:$1.1万
-
财政年份:2005
-
负责人:ELAN D LOUIS
-
依托单位:
MILD PARKINSONIAN SIGNS AND THE RISK OF ALZHEIMER'S DISEASE
-
批准号:6827805
-
项目类别:
-
资助金额:$12.69万
-
财政年份:2004
-
负责人:ELAN D LOUIS
-
依托单位:
Pathogenesis Of Essential Tremor: Cerebellar Metabolism
-
批准号:7109212
-
项目类别:
-
资助金额:$46.26万
-
财政年份:2003
-
负责人:ELAN D LOUIS
-
依托单位:
Pathogenesis Of Essential Tremor: Cerebellar Metabolism
-
批准号:7277644
-
项目类别:
-
资助金额:$46.04万
-
财政年份:2003
-
负责人:ELAN D LOUIS
-
依托单位:
Pathogenesis of Essential Tremor: Cerebellar Metabolism
-
批准号:7941850
-
项目类别:
-
资助金额:$65.26万
-
财政年份:2003
-
负责人:ELAN D LOUIS
-
依托单位:
Pathogenesis Of Essential Tremor: Cerebellar Metabolism
-
批准号:6789373
-
项目类别:
-
资助金额:$46.91万
-
财政年份:2003
-
负责人:ELAN D LOUIS
-
依托单位:
Pathogenesis of Essential Tremor: Cerebellar Metabolism
-
批准号:8312599
-
项目类别:
-
资助金额:$64.91万
-
财政年份:2003
-
负责人:ELAN D LOUIS
-
依托单位:
Pathogenesis of Essential Tremor: Cerebellar Metabolism
-
批准号:8109864
-
项目类别:
-
资助金额:$65.06万
-
财政年份:2003
-
负责人:ELAN D LOUIS
-
依托单位:
Pathogenesis Of Essential Tremor: Cerebellar Metabolism
-
批准号:6686189
-
项目类别:
-
资助金额:$46.18万
-
财政年份:2003
-
负责人:ELAN D LOUIS
-
依托单位:
Risk Factors Underlying Essential Tremor
-
批准号:7045040
-
项目类别:
-
资助金额:$1.25万
-
财政年份:2003
-
负责人:ELAN D LOUIS
-
依托单位:
Pathogenesis Of Essential Tremor: Cerebellar Metabolism
-
批准号:6924552
-
项目类别:
-
资助金额:$46.22万
-
财政年份:2003
-
负责人:ELAN D LOUIS
-
依托单位:
Pathogenesis of Essential Tremor: Cerebellar Metabolism
-
批准号:7690434
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2001
-
负责人:ELAN D LOUIS
-
依托单位:
FUNCTIONAL ASSESSMENT OF ESSENTIAL TREMOR (ET)
-
批准号:6567794
-
项目类别:
-
资助金额:$19.29万
-
财政年份:2001
-
负责人:ELAN D LOUIS
-
依托单位:
WASHINGTON HEIGHTS INWOOD AREA ESSENTIAL TREMOR STUDY
-
批准号:6567713
-
项目类别:
-
资助金额:$19.29万
-
财政年份:2001
-
负责人:ELAN D LOUIS
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: